Endocyte and ITM have entered a supply agreement under which ITM will supply the medical radioisotope no-carrier-added lutetium, EndolucinBeta^®, to support clinical supply of Lu-PSMA-617 for the phase 3 VISION trial expected to be initiated by Endocyte in the second quarter of 2018.

“ITM has been an innovator in the development of the highly purified form of lutetium-177, an integral component of the ¹⁷⁷Lu-PSMA-617 therapy for the investigational treatment of prostate cancer,” said Mike Sherman, president and chief executive officer of Endocyte. “We have made a strategic decision to utilize EndolucinBeta^® because of its favorable properties which will be important due to ¹⁷⁷Lu-PSMA-617’s significant potential market opportunity and widespread use.”

“We are delighted to collaborate with Endocyte as they develop this important therapy for patients with prostate cancer,” said Steffen Schuster, chief executive officer of ITM. “In the past, promising results have already been observed by combining EndolucinBeta^® with disease-specific targeting molecules for Targeted Radionuclide Therapy.”